Sanofi Terminates Agreement with Maze Therapeutics Following FTC Opposition
December 11 2023 - 5:18PM
Dow Jones News
By Denny Jacob
Sanofi will terminate its proposed licensing agreement with Maze
Therapeutics following opposition from the Federal Trade
Commission.
The FTC on Monday said it would seek to block the healthcare
company's proposed acquisition of an exclusive license to Maze's
therapy in development for the treatment of Pompe disease. The
regulator's complaint alleges the deal would protect Sanofi's
monopoly and eliminate competition between Sanofi and Maze to
develop new Pompe drugs.
Sanofi said it respectfully disagrees with the FTC's action and
its partnership with Maze was designed to apply its resources to
accelerate the development of MZE001.
"The delay associated with a long litigation has led Sanofi to
conclude that it would not be in the best interests of patients to
contest this litigation and Sanofi will therefore be terminating
the agreement with Maze in accordance with its terms," Sanofi
said.
The agreement between Sanofi and Maze for MZE001 was disclosed
on May 1.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 11, 2023 17:03 ET (22:03 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Oct 2024 to Nov 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Nov 2023 to Nov 2024
